- Conditions
- Lymphoma, B-Cell, Small Lymphocytic Lymphoma, Chronic Lymphocytic Leukemia, Waldenstrom Macroglobulinemia, Mantle Cell Lymphoma, Diffuse Large B Cell Lymphoma, Richter's Transformation, Follicular Lymphoma, Marginal Zone Lymphoma
- Interventions
- Nemtabrutinib
- Drug
- Lead sponsor
- ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 190 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2027
- U.S. locations
- 10
- States / cities
- Scottsdale, Arizona • Los Angeles, California • Denver, Colorado + 7 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 141
matching trials from the live ClinicalTrials.gov search.
- Conditions
- CLL/SLL, NHL, MCL, MZL, Lymphoplasmacytic Lymphoma, Waldenstrom Macroglobulinemia, Follicular Lymphoma, DLBCL, Richter Syndrome
- Interventions
- HMPL-760
- Drug
- Lead sponsor
- Hutchmed
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022
- U.S. locations
- 12
- States / cities
- Anaheim, California • Atlanta, Georgia • New Orleans, Louisiana + 9 more
- Conditions
- Recurrent Transformed Chronic Lymphocytic Leukemia, Refractory Transformed Chronic Lymphocytic Leukemia, Transformed Chronic Lymphocytic Leukemia to Diffuse Large B-Cell Lymphoma, Recurrent Transformed B-Cell Non-Hodgkin Lymphoma, Recurrent Transformed Non-Hodgkin Lymphoma, Refractory Transformed Non-Hodgkin Lymphoma, Refractory Transformed B-cell Non-Hodgkin Lymphoma, Refractory Transformed
- Interventions
- Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography, Cyclophosphamide, Fludarabine, Leukapheresis, Lisocabtagene Maraleucel, Lymph Node Biopsy, Positron Emission Tomography, Zanubrutinib
- Procedure · Drug · Biological
- Lead sponsor
- Aseel Alsouqi
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 3
- States / cities
- New York, New York • Columbus, Ohio • Salt Lake City, Utah
- Conditions
- Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
- Interventions
- Rituximab, Zanubrutinib
- Biological · Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
- Interventions
- Ibrutinib, Bendamustine hydrochloride, Rituximab, Placebo
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 578 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2019
- U.S. locations
- 42
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Berkeley, California + 39 more
- Conditions
- Atrial Fibrillation, Supraventricular Arrhythmia, Ventricular Arrhythmias and Cardiac Arrest, Chronic Lymphocytic Leukemia, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
- Interventions
- Medtronic LINQ-2 Insertable Cardiac Monitor (ILR)
- Device
- Lead sponsor
- Northwell Health
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2030
- U.S. locations
- 1
- States / cities
- New Hyde Park, New York
- Conditions
- Stage I Chronic Lymphocytic Leukemia, Stage II Chronic Lymphocytic Leukemia, Stage III Chronic Lymphocytic Leukemia, Stage IV Chronic Lymphocytic Leukemia
- Interventions
- Ibrutinib, Laboratory Biomarker Analysis
- Drug · Other
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2026
- U.S. locations
- 1
- States / cities
- Jacksonville, Florida
- Conditions
- Leukemia, Lymphocytic, Chronic, B-Cell
- Interventions
- Zanubrutinib Pill, Venetoclax Pill, Obinutuzumab Injection
- Drug
- Lead sponsor
- Weill Medical College of Cornell University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL)
- Interventions
- Acalabrutinib, Venetoclax
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 130 Years
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2033
- U.S. locations
- 4
- States / cities
- Boston, Massachusetts • Charlotte, North Carolina • Durham, North Carolina + 1 more
- Conditions
- Chronic Lymphocytic Leukemia, Lymphoma, Small Lymphocytic
- Interventions
- Pacritinib, Ibrutinib
- Drug
- Lead sponsor
- University of Michigan Rogel Cancer Center
- Other
- Eligibility
- 18 Years to 79 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 2
- States / cities
- Ann Arbor, Michigan • Rochester, Minnesota
- Conditions
- Chronic Lymphocytic Leukemia
- Interventions
- acalabrutinib, ACP-319
- Drug
- Lead sponsor
- Acerta Pharma BV
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2026
- U.S. locations
- 3
- States / cities
- Columbus, Ohio • Hermitage, Tennessee • Fort Worth, Texas
- Conditions
- B-cell Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
- Interventions
- PCI-32765
- Drug
- Lead sponsor
- Pharmacyclics LLC.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 133 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 10
- States / cities
- Stanford, California • New York, New York • Columbus, Ohio + 7 more
- Conditions
- B Cell Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia, Waldenstrom Macroglobulinemia
- Interventions
- AVL-292
- Drug
- Lead sponsor
- Celgene
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 113 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2015
- U.S. locations
- 13
- States / cities
- Huntsville, Alabama • Tucson, Arizona • La Jolla, California + 10 more
- Conditions
- Leukemia
- Interventions
- Heavy Water (2H2O), PCI-32765
- Other · Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2018
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
- Interventions
- Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Pirtobrutinib, Venetoclax
- Procedure · Drug
- Lead sponsor
- Kerry Rogers
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Small Lymphocytic Lymphoma (SLL), Chronic Lymphocytic Leukemia (CLL)
- Interventions
- Bruton's tyrosine kinase inhibitor, B-Cell Lymphoma 2 Protein Inhibitor
- Drug
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 1
- States / cities
- Tampa, Florida
- Conditions
- Chronic Lymphocytic Leukemia
- Interventions
- Sonrotoclax, Zanubrutinib, Acalabrutinib, Venetoclax
- Drug
- Lead sponsor
- BeOne Medicines
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 22
- States / cities
- Duarte, California • Orange, California • Palo Alto, California + 19 more
- Conditions
- Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia
- Interventions
- Nemtabrutinib
- Drug
- Lead sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
- NIH
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Chronic Lymphocytic Leukemia, Ibrutinib Resistance
- Interventions
- Ibrutinib, Laboratory Biomarker Analysis, Venetoclax
- Drug · Other
- Lead sponsor
- Ohio State University Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2026
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Chronic Lymphocytic Leukemia, Leukemia
- Interventions
- Ibrutinib, Fludarabine, Cyclophosphamide, Rituximab
- Drug
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 85 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2027
- U.S. locations
- 9
- States / cities
- Coral Gables, Florida • Deerfield Beach, Florida • Miami, Florida + 4 more
- Conditions
- Leukemia, Lymphocytic, Chronic, B-Cell, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
- Interventions
- Tafasitamab, Idelalisib, Venetoclax
- Biological · Drug
- Lead sponsor
- MorphoSys AG
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2021
- U.S. locations
- 3
- States / cities
- Jacksonville, Florida • Rochester, Minnesota • Columbus, Ohio
- Conditions
- Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
- Interventions
- Pirtobrutinib, Idelalisib, Bendamustine, Rituximab
- Drug
- Lead sponsor
- Loxo Oncology, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 238 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 46
- States / cities
- Daphne, Alabama • Mobile, Alabama • Glendale, Arizona + 41 more
- Conditions
- Lymphocytic Leukemia, Chronic, Lymphoma, Small Lymphocytic
- Interventions
- IPI-145 (duvelisib), Obinutuzumab
- Drug
- Lead sponsor
- SecuraBio
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 6
- States / cities
- La Jolla, California • Boston, Massachusetts • Hackensack, New Jersey + 3 more
- Conditions
- Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
- Interventions
- Ibrutinib, Fludarabine
- Drug
- Lead sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2034
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland